Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9Y6G9
UPID:
DC1L1_HUMAN
Alternative names:
Dynein light chain A; Dynein light intermediate chain 1, cytosolic
Alternative UPACC:
Q9Y6G9; A2RRG7; Q53HC8; Q53HK7
Background:
Cytoplasmic dynein 1 light intermediate chain 1, also known as Dynein light chain A and Dynein light intermediate chain 1, cytosolic, plays a crucial role in the cytoplasmic dynein 1 complex. This protein is essential for the retrograde motility of vesicles and organelles along microtubules, facilitating the transport of pericentrin and ensuring progress through the spindle assembly checkpoint. Its phosphorylated form is key in selectively removing MAD1L1 and MAD1L2 from kinetochores.
Therapeutic significance:
Understanding the role of Cytoplasmic dynein 1 light intermediate chain 1 could open doors to potential therapeutic strategies.